| Bioactivity | LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease[1][2]. | ||||||||||||
| In Vivo | LY3372689 shows a dose-dependent change in OGA enzyme occu-pancy (EO) following a single oral dose with a maximum EO of greater than 90% in rat[1]. | ||||||||||||
| Name | LY3372689 | ||||||||||||
| CAS | 2241514-56-5 | ||||||||||||
| Formula | C16H22FN5O3S | ||||||||||||
| Molar Mass | 383.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sergey Shcherbinin, et al. Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer's & Dementia. 07 December 2020 . [2]. Nicolas Jacques Francois Dreyfus, et al. N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor. Patent WO2018140299A1. |
LY3372689
CAS: 2241514-56-5 F: C16H22FN5O3S W: 383.44
LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies r
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.